Design, synthesis, and biological evaluation of target water-soluble hydroxamic acid-based HDACi derivatives as prodrugs

被引:14
作者
Li, Jun [1 ,2 ]
Zhu, Yedan [3 ]
Xie, Miaohong [1 ]
Zhang, Qian [1 ]
Du, Wenting [1 ]
机构
[1] Hangzhou Med Coll, Sch Pharm, 481 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China
[2] Univ Georgia, Dept Chem, Athens, GA 30602 USA
[3] Zhejiang Fangzheng Calibrat Co Ltd, Hangzhou, Zhejiang, Peoples R China
关键词
belinostat; histone deacetylase inhibitor; prodrug; vorinostat; water soluble; HISTONE DEACETYLASES; ADEPT; CANCER;
D O I
10.1111/cbdd.13577
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Four compounds T1, T2, T3, and T4 were designed and synthesized as Vorinostat and Belinostat derivatives being the target water-soluble prodrugs. The water solubility of Vorinostat derivatives, T1 and T2, exhibited 400- to 600-fold higher than that of Vorinostat, and Belinostat derivatives, T3 and T4, showed 600- to 750-fold higher than that of Belinostat. Four compounds were evaluated for their inhibitory activities against tumor cell lines HT-29 and Hut-78 in the absence or presence of beta-D-glucuronidase. The inhibitory effects of T1 and T2 were comparable to Vorinostat in the presence of beta-D-glucuronidase, but were higher than 10 mu M in the absence of beta-D-glucuronidase. Therefore, T1 and T2 are promising candidates for in vivo investigations with high potential to be the target water-soluble prodrugs. IC50 values of Belinostat derivatives T3 and T4 were not affected by beta-D-glucuronidase, but T3 and T4 had the excellent cell proliferation inhibition on Hut-78.
引用
收藏
页码:1760 / 1767
页数:8
相关论文
共 18 条
[1]   Antibody-directed enzyme prodrug therapy (ADEPT) for cancer [J].
Bagshawe, KD ;
Sharma, SK ;
Begent, RHJ .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (11) :1777-1789
[2]   Small Molecules as SIRT Modulators [J].
Bai, Xinfa ;
Yao, Lei ;
Ma, Xuan ;
Xu, Xiangming .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2018, 18 (13) :1151-1157
[3]   Histone Deacetylase Inhibition Increases Levels of Choline Kinase a and Phosphocholine Facilitating Noninvasive Imaging in Human Cancers [J].
Beloueche-Babari, Mounia ;
Arunan, Vaitha ;
Troy, Helen ;
Poele, Robert H. Te ;
Fong, Anne-Christine Wong Te ;
Jackson, L. Elizabeth ;
Payne, Geoffrey S. ;
Griffiths, John R. ;
Judson, Ian R. ;
Workman, Paul ;
Leach, Martin O. ;
Chung, Yuen-Li .
CANCER RESEARCH, 2012, 72 (04) :990-1000
[4]   Targeting Histone Deacetylases in Diseases: Where Are We? [J].
Benedetti, Rosaria ;
Conte, Mariarosaria ;
Altucci, Lucia .
ANTIOXIDANTS & REDOX SIGNALING, 2015, 23 (01) :99-126
[5]   First enzymatically activated Taxotere prodrugs designed for ADEPT and PMT [J].
Bouvier, E ;
Thirot, S ;
Schmidt, F ;
Monneret, C .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (05) :969-977
[6]   A new paclitaxel prodrug for use in ADEPT strategy [J].
Bouvier, E ;
Thirot, S ;
Schmidt, F ;
Monneret, C .
ORGANIC & BIOMOLECULAR CHEMISTRY, 2003, 1 (19) :3343-3352
[7]   Synthesis and evaluation of water-soluble docetaxel prodrugs-docetaxel esters of malic acid [J].
Du, Wenting ;
Hong, Lan ;
Yao, Tongwei ;
Yang, Xiaochun ;
He, Qiaojun ;
Yang, Bo ;
Hu, Yongzhou .
BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (18) :6323-6330
[8]   New Taxol® (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy [J].
El Alaoui, Abdessamad ;
Saha, Nabendu ;
Schmidt, Frederic ;
Monneret, Claude ;
Florent, Jean-Claude .
BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (14) :5012-5019
[9]   After the grape rush: Sirtuins as epigenetic drug targets in neurodegenerative disorders [J].
Huber, Kilian ;
Superti-Furga, Giulio .
BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (12) :3616-3624
[10]  
Kelly WK, 2003, CLIN CANCER RES, V9, P3578